Midazolam Nasal — Membership Pricing

Other medications in Neurological

• Natalizumab (Neurology)
• Nusinersen
• Ocrelizumab
• Ofatumumab
• Oxcarbazepine
• Perampanel
• Phenobarbital
• Ponesimod

About Midazolam Nasal

Midazolam nasal is a crucial medication used for the emergency treatment of seizure clusters in patients aged 12 and older. Designed for rapid action and ease of administration, it offers a vital intervention when every second counts. TheDrugClub is dedicated to helping members access essential medications like midazolam nasal at more manageable prices, ensuring peace of mind during critical moments.

What is Midazolam Nasal and What Does It Treat?

Midazolam nasal spray is an important prescription medication specifically approved for the acute treatment of seizure clusters (also known as acute repetitive seizures or breakthrough seizures) in individuals 12 years of age and older. Unlike daily maintenance medications, midazolam nasal is an emergency rescue drug, designed to be administered quickly by a caregiver or family member when a patient experiences a cluster of seizures outside of a hospital setting. Its ease of use and rapid delivery make it a valuable tool in preventing prolonged seizures or status epilepticus.

How Does Midazolam Nasal Work?

Midazolam belongs to a class of drugs known as benzodiazepines. These medications work by enhancing the effects of a natural calming neurotransmitter in the brain called gamma-aminobutyric acid (GABA). By boosting GABA's activity, midazolam helps to slow down overactive electrical signals in the brain that cause seizures. The nasal formulation allows the medication to be absorbed quickly through the nasal passages directly into the bloodstream, reaching the brain rapidly to help stop a seizure cluster efficiently. This fast-acting mechanism is crucial in emergency situations.

Understanding Typical Costs

As a specialized emergency medication, midazolam nasal can carry a significant cash price without insurance or adequate coverage. Costs can vary widely based on the specific brand or generic availability, pharmacy pricing, and your location. A single dose or a package containing multiple doses can range from several hundred to over a thousand dollars. These substantial costs can be a barrier for many patients and families who rely on this life-saving treatment.

How TheDrugClub Can Help You Save

TheDrugClub understands the financial burden of essential medications. For members, accessing midazolam nasal can be more affordable through our program. Depending on your specific plan and the medication's formulary status, you may be eligible for active-formulary benefits, where we help you navigate your existing prescription coverage to maximize savings. For those without coverage, or for medications not on their formulary, TheDrugClub offers significant discount pricing to dramatically reduce out-of-pocket expenses.

It's important to remember that TheDrugClub is a savings program

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Midazolam Nasal is approved for (FDA label)

NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. NAYZILAM is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: January 19, 2023.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Midazolam Nasal (FDA label)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death . Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.2) ] . The use of benzodiazepines, including NAYZILAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing NAYZILAM and throughout treatment, assess each patient's risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2) ]. The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although NAYZILAM is indicated only for intermittent use [see Indications and Usage (1) and Dosage and Administration (2) ] , if used more frequently than recommended abrupt discontinuation or rapid dosage reduction of NAYZILAM may precipitate acute withdrawal reactions, which can be life-threatening.

Source: FDA prescribing information (DailyMed). Set ID: 2b29422e-54d5-4a49-8522-e9cf752368c3. SPL document ID: 5776d86f-c632-429f-ac0b-88ade1a3930c. Label effective date: January 19, 2023. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Midazolam Nasal (FDA label)

NAYZILAM is supplied as a single-dose nasal spray unit containing 5 mg of midazolam in 0.1 mL solution. Single-dose nasal spray unit containing 5 mg midazolam per 0.1 mL solution. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2b29422e-54d5-4a49-8522-e9cf752368c3. SPL document ID: 5776d86f-c632-429f-ac0b-88ade1a3930c. Label effective date: January 19, 2023. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Midazolam Nasal (FDA label)

The following serious adverse reactions are discussed in more detail in other sections of the labeling: Risks from Concomitant Use with Opioids [see Warnings and Precautions (5.1) ] Abuse, Misuse, and Addiction [see Warnings and Precautions (5.2) ] Dependence and Withdrawal Reactions After Use of NAYZILAM More Frequently Than Recommended [see Warnings and Precautions (5.3) ] Risks of Cardiorespiratory Adverse Reactions [see Warnings and Precautions (5.4) ] CNS Depression from Concomitant Use with Other CNS Depressants or Moderate or Strong CYP3A4 Inhibitors [see Warnings and Precautions (5.5) ] Suicidal Behavior and Ideation [see Warnings and Precautions (5.6) ] Impaired Cognitive Function [see Warnings and Precautions (5.7) ] Glaucoma [see Warnings and Precautions (5.8) ] Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions (5.9) ] Other Adverse Reactions [see Warnings and Precautions (5.10) ] The most common adverse reactions (≥5% in any NAYZILAM treatment group) were somnolence, headache, nasal discomfort, throat irritation, and rhinorrhea ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-844-599-2273 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 2b29422e-54d5-4a49-8522-e9cf752368c3. SPL document ID: 5776d86f-c632-429f-ac0b-88ade1a3930c. Label effective date: January 19, 2023. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Midazolam Nasal (FDA label)

NAYZILAM is contraindicated in patients with: Known hypersensitivity to midazolam. Acute narrow-angle glaucoma [see Warnings and Precautions (5.8) ]. Patients with hypersensitivity to midazolam ( 4 ) Patients with acute narrow-angle glaucoma ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 2b29422e-54d5-4a49-8522-e9cf752368c3. SPL document ID: 5776d86f-c632-429f-ac0b-88ade1a3930c. Label effective date: January 19, 2023. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Midazolam Nasal (FDA label)

CNS Depression From Concomitant Use With Other CNS Depressants or Moderate or Strong CYP3A4 Inhibitors : May cause an increased CNS-depressant effect when used with alcohol or other CNS depressants. Concomitant use with moderate or strong CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. ( 5.5 , 7.3 ) Suicidal Behavior and Ideation: Antiepileptic drugs increase the risk of suicidal ideation and behavior. ( 5.6 ) Impaired Cognitive Function: Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours. ( 5.7 ) Glaucoma: NAYZILAM can increase intraocular pressure in patients with glaucoma.

Source: FDA prescribing information (DailyMed). Set ID: 2b29422e-54d5-4a49-8522-e9cf752368c3. SPL document ID: 5776d86f-c632-429f-ac0b-88ade1a3930c. Label effective date: January 19, 2023. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Midazolam Nasal (FDA label)

Table 3: Clinically Significant Drug Interactions With NAYZILAM 7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamil Strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin 7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

Source: FDA prescribing information (DailyMed). Set ID: 2b29422e-54d5-4a49-8522-e9cf752368c3. SPL document ID: 5776d86f-c632-429f-ac0b-88ade1a3930c. Label effective date: January 19, 2023. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.